<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03643952</url>
  </required_header>
  <id_info>
    <org_study_id>3009-029</org_study_id>
    <secondary_id>MK-3009-029</secondary_id>
    <secondary_id>184155</secondary_id>
    <nct_id>NCT03643952</nct_id>
  </id_info>
  <brief_title>Safety, Efficacy, and Pharmacokinetics (PK) of Daptomycin (MK-3009) in Japanese Pediatric Subjects With Complicated Skin and Soft Tissue Infections (cSSTI) and Bacteremia (MK-3009-029)</brief_title>
  <official_title>A Phase II Open-Label, Single-arm Clinical Trial to Study the Safety, Efficacy and Pharmacokinetics of MK-3009 (Daptomycin) in Japanese Pediatric Participants Aged 1 to 17 Years With cSSTI or Bacteremia Caused by Gram-positive Cocci</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, efficacy and pharmacokinetic (PK)
      parameters of daptomycin for injection in Japanese pediatric participants aged 1 to 17 years
      with complicated skin and soft tissue infection (cSSTI) or bacteremia caused by Gram-positive
      cocci.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 6, 2018</start_date>
  <completion_date type="Actual">April 7, 2020</completion_date>
  <primary_completion_date type="Actual">April 7, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants with an Adverse Event</measure>
    <time_frame>Up to 14 days following end of therapy (EOT) (up to 56 days)</time_frame>
    <description>An adverse event (AE) is any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an adverse event. The percentage of participants discontinued from the study due to an AE will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants that Discontinued Study Due to an AE</measure>
    <time_frame>Up to 42 days</time_frame>
    <description>An AE is any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an adverse event. The percentage of participants discontinued from the study due to an AE will be reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Clinical Success</measure>
    <time_frame>Up to 10 days following EOT (up to 52 days)</time_frame>
    <description>The investigator's assessment of clinical response will be conducted at the Test of Cure (TOC) visit, approximately 10 days after the completion of therapy. Clinical success is defined as 1) resolution of clinically significant signs and symptoms associated with admission infection and no further antibiotic therapy required, OR 2) partial resolution of clinical signs or symptoms of infection with no further antibiotic therapy required. The percentage of participants with clinical success will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Subject-Level Microbiological Success</measure>
    <time_frame>Up to 10 days following EOT (up to 52 days)</time_frame>
    <description>The investigator's assessment of subject-level microbiological response will be conducted at the TOC visit, approximately 10 days after the completion of therapy. Subject-level microbiological success is defined as 1) absence or presumed absence of all baseline infecting pathogens, AND 2) no gram-positive superinfection or gram-positive new infection. The percentage of participants with subject-level microbiological success will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration Time Curve from Time 0 to 24 Hours (AUC 0-24) Parameters</measure>
    <time_frame>At designated time points on Day 3</time_frame>
    <description>Plasma samples will be used to determine the AUC0-24 of daptomycin for each infection type and age category.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Maximum Concentration (Cmax)</measure>
    <time_frame>At designated time points on Day 3</time_frame>
    <description>Plasma samples will be used to determine the Cmax of daptomycin for each infection type and age category.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Time to Reach Maximum Plasma Concentration (Tmax)</measure>
    <time_frame>At designated time points on Day 3</time_frame>
    <description>Plasma samples will be used to determine the Tmax of daptomycin for each infection type and age category.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Total Body Clearance of Steady State (CLss/F)</measure>
    <time_frame>At designated time points on Day 3</time_frame>
    <description>Plasma samples will be used to determine the CLss of daptomycin for each infection type and age category.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Volume of Distribution at Steady State (Vss)</measure>
    <time_frame>At designated time points on Day 3</time_frame>
    <description>Plasma samples will be used to determine the Vss of daptomycin for each infection type and age category.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Apparent Half-life (t½)</measure>
    <time_frame>At designated time points on Day 3</time_frame>
    <description>Plasma samples will be used to determine the t½ of daptomycin for each infection type and age category.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Bacteremia</condition>
  <condition>Soft Tissue Infections</condition>
  <condition>Skin Diseases, Infectious</condition>
  <arm_group>
    <arm_group_label>Daptomycin-cSSTI or Bacteremia: Age 1-17</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants aged 1 to 17 years old with cSSTI or bacteremia will receive daptomycin intravenously every 24 hours (q24hrs) for either 5-14 days for cSSTI or for 5-42 days for bacteremia.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daptomycin for Injection</intervention_name>
    <description>Once daily administration of 5, 7, 9, 10, or 12 mg/kg intravenous (IV) daptomycin infused with 25-50 mL saline over 30-60 minutes depending upon infection type and age level.</description>
    <arm_group_label>Daptomycin-cSSTI or Bacteremia: Age 1-17</arm_group_label>
    <other_name>MK-3009</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Requires treatment for cSSTI or bacteremia.

          -  Is male or female Japanese aged ≥ 1 to ≤ 17 years on the day of signing informed
             consent.

          -  As a male participant, has agreed to use contraception during the treatment period and
             for at least 14 days after the last dose of study treatment and refrain from donating
             sperm during this period.

          -  As a female participant, has agreed to participate if she is not pregnant, not
             breastfeeding, and at least one of the following conditions applies: not a woman of
             childbearing potential (WOCBP) or a WOCBP who agrees to follow the contraceptive
             guidance during the treatment period and for at least 14 days after the last dose of
             study treatment.

          -  Has agreed to allow any bacterial isolates obtained from protocol-required specimens
             related to the current infection to be provided the Central Microbiology Reference
             Laboratory for study-related microbiological testing, long-term storage, and other
             future testing.

        cSSTI Participants

          -  Has cSSTI known or suspected to be caused by Gram-positive cocci that requires
             intravenous antibiotic treatment and diagnosed with either Gram stain or culture.

          -  Has at least 3 of the following clinical signs and symptoms associated with the cSSTI:
             pain, tenderness to palpation, temperature &gt;37.0°C axillary or &gt;37.5°C oral or &gt;38.0°
             C rectal, forehead, or aural, white blood count (WBC) &gt;12,000/mm^3 or ≥10% bands,
             swelling and/or induration, erythema (&gt;1 cm beyond edge of wound or abscess), pus
             formation, CRP &gt; upper limited of normal.

        Bacteremia Participants

          -  Have proven bacteremia with pathogen identification of Gram-positive cocci at least
             one blood culture bottle by conventional culture methods or by a rapid diagnostic test
             in screening period.

          -  Have probable bacteremia with a blood culture result demonstrating Gram-positive cocci
             by Gram stain in screening period.

        Exclusion Criteria:

          -  Has received previous systemic antimicrobial therapy that is effective against Gram
             positive cocci and exceeding 72 hours duration administered at any time during the 96
             hours prior to the first dose of study drug.

          -  Has a known infection caused solely by Gram-negative pathogen(s), fungus(i) or
             virus(es).

          -  Has pneumonia (septic emboli in the lung is not an exclusion if clear evidence of
             source of infection is other than lungs), empyema, meningitis, endocarditis, or
             osteoarticular infection.

          -  Has a history of or current rhabdomyolysis.

          -  Is anticipated to require non-study systemic antibiotics that may be potentially
             effective against Gram-positive pathogen(s).

          -  Has shock or hypotension unresponsive to fluids or vasopressors for ≥ 4 hours.

          -  Has significant allergy/hypersensitivity or intolerance to daptomycin.

          -  Has renal insufficiency.

          -  Has a history of clinically significant (as assessed by the Investigator) muscular
             disease, nervous system or seizure disorder, including unexplained muscular weakness,
             history of peripheral neuropathy, Guillain-Barre or spinal cord injury; previous
             uncomplicated febrile seizure allowed.

          -  Has a history or current evidence of any condition, therapy, lab abnormality or other
             circumstance that might expose the participant to risk by participating in the trial,
             confound the results of the trial, or interfere with the participant's participation
             for the full duration of the trial.

          -  Is a female who is pregnant or is expecting to conceive (or is a male partner of a
             female who is expecting to conceive), is breastfeeding, or plans to breastfeed prior
             to completion of the study.

          -  Is currently participating in, or has participated in, any other clinical study
             involving the administration of investigational or experimental medication (not
             licensed by regulatory agencies) at the time of the presentation or during the
             previous 30 days prior to screening or is anticipated to participate in such a
             clinical study during the course of this trial.

          -  Has previously participated in this study at any time.

          -  Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling or
             child) who is investigational site or sponsor staff directly involved with this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Japan Community Health Care Organization Chukyo Hospital ( Site 0030)</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>457-8510</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Japan Community Health care Organization Kyushu Hospital ( Site 0016)</name>
      <address>
        <city>Kitakyushu</city>
        <state>Fukuoka</state>
        <zip>806-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maebashi Red Cross Hospital ( Site 0012)</name>
      <address>
        <city>Maebashi</city>
        <state>Gunma</state>
        <zip>371-0811</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kobe University Hospital ( Site 0015)</name>
      <address>
        <city>Kobe</city>
        <state>Hyogo</state>
        <zip>650-0017</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shikoku Medical Center for Children and Adults ( Site 0027)</name>
      <address>
        <city>Zentsuji</city>
        <state>Kagawa</state>
        <zip>765-8507</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Showa University Fujigaoka Hospital ( Site 0023)</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>227-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanagawa Children's Medical Center ( Site 0025)</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>232-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization National Mie Hospital ( Site 0002)</name>
      <address>
        <city>Tsu</city>
        <state>Mie</state>
        <zip>514-0125</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Beppu Medical Center ( Site 0003)</name>
      <address>
        <city>Beppu</city>
        <state>Oita</state>
        <zip>874-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Metropolitan Children's Medical Center ( Site 0004)</name>
      <address>
        <city>Fuchu</city>
        <state>Tokyo</state>
        <zip>183-8561</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiba University Hospital ( Site 0005)</name>
      <address>
        <city>Chiba</city>
        <zip>260-8677</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiba Children's Hospital ( Site 0024)</name>
      <address>
        <city>Chiba</city>
        <zip>266-0007</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Kumamoto Medical Center ( Site 0018)</name>
      <address>
        <city>Kumamoto</city>
        <zip>860-0008</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka City General Hospital ( Site 0020)</name>
      <address>
        <city>Osaka</city>
        <zip>534-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saitama City Hospital ( Site 0008)</name>
      <address>
        <city>Saitama</city>
        <zip>336-8522</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nihon University Itabashi Hospital ( Site 0029)</name>
      <address>
        <city>Tokyo</city>
        <zip>173-8610</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>August 21, 2018</study_first_submitted>
  <study_first_submitted_qc>August 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 23, 2018</study_first_posted>
  <last_update_submitted>June 9, 2020</last_update_submitted>
  <last_update_submitted_qc>June 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>methicillin-resistant S. aureus (MRSA) infections</keyword>
  <keyword>complicated skin and soft tissue infections (cSSTI)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Bacteremia</mesh_term>
    <mesh_term>Soft Tissue Infections</mesh_term>
    <mesh_term>Skin Diseases, Infectious</mesh_term>
    <mesh_term>Skin Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Daptomycin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

